Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Germany's Merck plans divestment of biosimilars business

Merck has a strategic alliance with India's Dr Reddy's Labs to co-develop multiple cancer drugs

BS B2B Bureau  |  Darmstadt, Germany 

Germany's Merck plans divestment of biosimilars business

KGaA, the German firm that specialises in chemical, and life sciences sectors, is planning to divest its business. “is in advanced stages of negotiations to divest the business and the transaction is expected to close in 2017,” said the company in its 2016 annual report. Biosimilar unit comes under Merck’s healthcare business vertical, which also comprises biopharma, consumer health and Allergopharma businesses.

are a small, but fast-growing part of the market. In 2016, sales are expected to reach $ 1.4 billion annually before growing to $ 8 billion in 2022, according to EvaluatePharma.

is developing a portfolio focused on oncology and autoimmune diseases through both in-house research and development expertise in biologics and partnerships with other biosimilar players. It has strategic alliances with India’s Laboratories to co-develop multiple drugs and with Bionovis in Brazil to supply the Brazilian market with biological products under the Productive Development Partnership (PDP) policy of the Brazilian Ministry of Health.

With Dr Reddy’s, signed a partnership agreement in June 2012 to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). As per the pact, was expected to lead early product development & complete phase I development, with taking over manufacturing of the compounds and leading phase III development.

RECOMMENDED FOR YOU

Germany's Merck plans divestment of biosimilars business

Merck has a strategic alliance with India's Dr Reddy's Labs to co-develop multiple cancer drugs

Merck has a strategic alliance with India's Dr Reddy's Labs to co-develop multiple cancer drugs
KGaA, the German firm that specialises in chemical, and life sciences sectors, is planning to divest its business. “is in advanced stages of negotiations to divest the business and the transaction is expected to close in 2017,” said the company in its 2016 annual report. Biosimilar unit comes under Merck’s healthcare business vertical, which also comprises biopharma, consumer health and Allergopharma businesses.

are a small, but fast-growing part of the market. In 2016, sales are expected to reach $ 1.4 billion annually before growing to $ 8 billion in 2022, according to EvaluatePharma.

is developing a portfolio focused on oncology and autoimmune diseases through both in-house research and development expertise in biologics and partnerships with other biosimilar players. It has strategic alliances with India’s Laboratories to co-develop multiple drugs and with Bionovis in Brazil to supply the Brazilian market with biological products under the Productive Development Partnership (PDP) policy of the Brazilian Ministry of Health.

With Dr Reddy’s, signed a partnership agreement in June 2012 to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). As per the pact, was expected to lead early product development & complete phase I development, with taking over manufacturing of the compounds and leading phase III development.

image
Business Standard
177 22

Germany's Merck plans divestment of biosimilars business

Merck has a strategic alliance with India's Dr Reddy's Labs to co-develop multiple cancer drugs

KGaA, the German firm that specialises in chemical, and life sciences sectors, is planning to divest its business. “is in advanced stages of negotiations to divest the business and the transaction is expected to close in 2017,” said the company in its 2016 annual report. Biosimilar unit comes under Merck’s healthcare business vertical, which also comprises biopharma, consumer health and Allergopharma businesses.

are a small, but fast-growing part of the market. In 2016, sales are expected to reach $ 1.4 billion annually before growing to $ 8 billion in 2022, according to EvaluatePharma.

is developing a portfolio focused on oncology and autoimmune diseases through both in-house research and development expertise in biologics and partnerships with other biosimilar players. It has strategic alliances with India’s Laboratories to co-develop multiple drugs and with Bionovis in Brazil to supply the Brazilian market with biological products under the Productive Development Partnership (PDP) policy of the Brazilian Ministry of Health.

With Dr Reddy’s, signed a partnership agreement in June 2012 to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). As per the pact, was expected to lead early product development & complete phase I development, with taking over manufacturing of the compounds and leading phase III development.

image
Business Standard
177 22